Insulin products are seemingly the new poster child for biopharma greed in America. The status was confirmed Wednesday when leaders of the House Energy and Commerce Committee sent letters to the CEOs of Eli Lilly and Co., Novo Nordisk A/S and Sanofi SA. Together, the three companies have pretty much a lock on the U.S. insulin market.